TerminatedPhase 2NCT03980938

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Studying Huntington disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
EIP Pharma Inc
Principal Investigator
John Alam, MD
EIP Pharma
Intervention
neflamapimod(drug)
Enrollment
15 enrolled
Eligibility
30-70 years · All sexes
Timeline
2019 – 2020

Study locations (1)

Collaborators

Voisin Consulting, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03980938 on ClinicalTrials.gov

Other trials for Huntington disease

Additional recruiting or active studies for the same condition.

See all trials for Huntington disease →

← Back to all trials